Gary is a registered U.S. patent attorney with a focus on issues facing companies in the life sciences sectors. He is a patent litigator who provides counsel on a broad range of patent-related matters and regularly conducts pre-suit investigations, intellectual property valuations and IP due diligence. Gary provides freedom-to-operate clearance reviews and opinions relating to infringement and validity, and develops patent procurement and patent prosecution strategies for domestic, international, and foreign jurisdictions. He has been involved in numerous post-grant proceedings (e.g., ex parte reexaminations and inter partes reviews) in front of the U.S. Patent and Trademark Office (USPTO). The post-grant proceedings have involved patents across diverse technology areas (e.g., medical devices, drug delivery systems, polymers, pharmaceuticals, new chemical entities, and process manufacturing).

Gary has a strong technical and scientific background, as well as extensive, firsthand experience in USPTO practice and procedure. For the past several years, Gary has devoted significant time to preparing opinions relating to pharmaceutical patents, and has prepared and served numerous Hatch Waxman “Paragraph IV” notice letters and detailed statements. He also has represented generic pharmaceutical companies in ANDA patent litigations.

In addition to his work in the pharmaceutical arena, Gary’s practice covers a variety of other technologies, including medical devices, drug delivery systems, natural products, nutraceuticals, polymers, biofuels, renewable energy, sustainable chemistry, process manufacturing, solar silicon purification, agriculture, pesticides and organic synthesis.

After earning his graduate degree in chemistry, Gary worked as a medicinal chemist at Sterling Winthrop Pharmaceuticals, where he designed and synthesized candidate inhibitors of the cysteine protease enzyme, Interleukin–1–ß Converting Enzyme (ICE), for the treatment of chronic inflammatory diseases. During law school, Gary worked as a law clerk in the patent group at SmithKline Beecham (now Glaxo SmithKline).

Gary has co-authored several peer-reviewed articles published in scientific journals and is a named inventor on several U.S. patents. He has been an invited lecturer in the United States, Europe and Asia on various IP matters, including freedom to operate, Paragraph IV opinions and IP valuation. He is also the owner and moderator of the Freedom to Operate (FTO) and IP Due Diligence discussion group on LinkedIn. In 2004, he was named by Super Lawyers as a “Rising Star.”  Gary is listed in the 2020 – 2022 Best Lawyers® in America annual editions.

In 2024 Gary earned accreditation as a Certified Valuation Analyst® (CVA®) with the National Association of Certified Valuators and Analysts (NACVA). NACVA trains and certifies financial professionals in business valuation and financial litigation services, including damages determinations. As a pharmaceutical patent litigator, Gary’s law practice includes financial and economic analysis of IP issues such as economic damages, commercial success, and licensing & transactions. As an entrepreneur, Gary is experienced with patent valuation, litigation finance, statistical modeling, financial projections, and the valuation of pre-commercialization and commercial-stage pharmaceutical assets—505b2 NDAs and PIV ANDAs.

REPRESENTATIVE CASES

Laboratoire HRA Pharma v. Teva Pharmaceuticals USA, Inc. (ulipristal)

Pack Pharmaceuticals v. Alza Corporation (glipizide)

Teva v. Allergan (cyclosporine)

Teva V. AstraZeneca (saxagliptin HCI)

Teva v. Eli Lilly (pemetrexed disodium)